AML in older patients: Are we making progress?

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 4, 2009, Pages 529-536

  Estey, Elihu ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukaemia; CRp; older; reduced intensity transplant; resistance; treatment induced death

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CLOFARABINE; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IDARUBICIN; LAROMUSTINE; NEW DRUG; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AWARENESS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CROWDING; CYTOGENETICS; DIET; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; MASK; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REVIEW; THROMBOCYTE COUNT; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CYTOGENETIC ANALYSIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROGNOSIS;

EID: 71749095535     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.08.007     Document Type: Review

References (28)

1. Thall P., and Estey E. Graphical methods for evaluating covariate effects in the Cox model. In: Crowley J. (Ed). Handbook of statistics in clinical oncology (2001), Marcel-Dekker, New York 411-433
2. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25 (2007) 1908-1915
3. Giles F.J., Borthakur G., Ravandi F., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. British Journal of Haematology 136 (2007) 624-627
4. Estey E., and Dohner H. Acute myeloid leukaemia. Lancet 368 (2006) 1894-1907
5. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 107 (2006) 3481-3485
6. Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113 (2009) 4179-4187
7. Erba H.P., Kantarjian H., Claxton D.F., et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood 112 (2008) 209 (abstr 558)
8. Giles F., Rizzieri D., Karp J., et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of Clinical Oncology 25 (2007) 25-31
9. Malfuson J.V., Etienne A., Turlure P., et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 93 (2008) 1806-1813
10. Burnett A.K., Milligan D., Prentice A.G., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109 (2007) 1114-1124
11. Hills R., O'Brien S., Karsten V., et al. A retrospective comparison of matched elderly patients treated with laromustine (Cloretazine®) or best supportive care or low dose ara-C in the LRF AML14 trial. Blood 112 (2008) 1017 (abstr 2960)
12. Faderl S., Ravandi F., Huang X., et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112 (2008) 1638-1645
13. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109 (2007) 1395-1400
14. Bertz H., Potthoff K., and Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. Journal of Clinical Oncology 21 (2003) 1480-1484
15. Freireich E.J., Gehan E.A., Sulman D., et al. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 14 (1961) 593-608
16. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21 (2003) 4642-4649
17. Estey E.H., Garcia-Manero G., Giles F.J., et al. Clinical relevance of CRp in untreated AML. Blood 106 (2005) 161a (abstr 541)
18. Etienne A., Charbonnier A., Prebet T., et al. Impact of CRi on outcome of elderly patients with untreated acute myeloid leukemia (AML). Blood 112 (2008) 1030 (abstr 2988)
19. Estey E.H., and Thall P.F. New designs for phase 2 clinical trials. Blood 102 (2003) 442-448
20. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1312-1320
21. Becker H., Marcucci G., Maharry K., et al. NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol 27 (2009) 356s (abstr 7000)
22. Appelbaum F.R., Kopecky K.J., Tallman M.S., et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135 (2006) 165-173
23. Breems D.A., van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26 (2008) 4791-4797
24. Woods W.G., Kobrinsky N., Buckley J.D., et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 87 (1996) 4979-4989
25. Sekeres M.A., Elson P., Kalaycio M.E., et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 113 (2009) 28-36
26. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106 (2006) 1090-1098
27. Gardner A., Mattiuzzi G., Faderl S., et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 26 (2008) 5684-5688
28. Cashen A.F., Schiller G.J., O'Donnell M.R., et al. Preliminary results of a multicenter phase II trial of 5-day decitabine as front-line therapy for elderly patients with acute myeloid leukemia (AML). Blood 112 (2008) 210 (abstr 560)